Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(6 sites)
United States
Start Midwest, Grand Rapids, Michigan Sarah Cannon Research Institute, Nashville, Tennessee France
Institut Gustave Roussy, Villejuif Spain
Hosp Univ Vall D Hebron, Barcelona Hosp. Univ. 12 de Octubre, Madrid